Skip to main content
. Author manuscript; available in PMC: 2018 Nov 1.
Published in final edited form as: Mol Cancer Ther. 2017 Sep 1;16(11):2473–2485. doi: 10.1158/1535-7163.MCT-16-0834

Figure 5. 7rh in combination with chemotherapy reduced DDR1-mediated signaling and tumorigenicity in a PDA xenograft model.

Figure 5

(A) Schematic representation of the animal experiment. (B–C) 7rh combined with a chemotherapy regimen (gemcitabine + nab-paclitaxel) enhanced the overall median of survival in a xenograft PDA model of human cell line AsPC-1. (D–K) Immunohistological analysis of PDA tumors demonstrated that 7rh, chemotherapy, and the combination regimen enhanced the presence of a more normal pancreatic landscape (H&E), significantly inhibited DDR1-mediated signaling, and significantly reduced the levels of the mesenchymal marker VIMENTIN and proliferation (PCNA), and enhanced the levels of apoptosis (CLEAVED CASPASE-3) and DNA damage (ƳH2AX). Error bars: (*, p < 0.05; **, p < 0.005; ***, p < 0.0005; ****, p < 0.00005) compared to the initial group; (^, p < 0.05; ^^, p < 0.005; ^^^, p < 0.0005; ^^^^, p < 0.00005) compared to the vehicle group, one-way ANOVA with Tukey’s MCT.